MSL: AML in Hematology/Oncology (Field-Based)

IQVIA; Miami (FL); On-site; USD 170,000 - 210,000; Full time

Job summary

IQVIA is seeking experienced Medical Science Liaisons to support a late-stage AML program. This field-based role engages hematologists, oncologists and researchers to facilitate scientific exchange, communicate clinical data and gather insights on MRD, relapse risk and evolving standards of care.

The MSL will build relationships with investigators, KOLs and institutions, support investigator-initiated studies, and ensure compliant, evidence-based medical interactions.

Qualifications

• Advanced degree in a scientific or clinical field (e.g., PharmD, MD, DO, PhD, NP, PA) is required.
• Minimum 4 years of MSL or relevant hematology/oncology experience.
• Strong communication and presentation skills for diverse audiences.

Responsibilities

• Develop and maintain relationships with investigators, KOLs, and priority institutions.
• Engage in compliant scientific discussions on AML, hematologic malignancies, and evolving care standards.
• Communicate complex data clearly to physicians, researchers, and multidisciplinary teams.
• Support disease-state education, advisory boards, and investigator meetings.
• Document scientific interactions and insights in CRM systems.
• Identify medical education needs and support trial awareness/site engagement.
• Assist investigators with study development and operational support.
• Monitor developments in the competitive landscape and guideline evolution.

Skills

CRM proficiency

MS Office Suite

Travel readiness

Scientific communication

Cross-functional collaboration

Education

Advanced clinical or scientific degree

Tools

Microsoft Teams

CRM platforms

Job description

IQVIA is seeking experienced Medical Science Liaisons to support a late-stage AML program. This field-based role engages hematologists, oncologists and researchers to facilitate scientific exchange, communicate clinical data and gather insights on MRD, relapse risk and evolving standards of care.

The MSL will build relationships with investigators, KOLs and institutions, support investigator-initiated studies, and ensure compliant, evidence-based medical interactions.